MSB.AX - Mesoblast Limited

ASX - ASX Delayed price. Currency in AUD
1.1750
+0.0050 (+0.43%)
At close: 4:11PM AEDT
Stock chart is not supported by your current browser
Previous close1.1700
Open1.1700
Bid1.170 x 0
Ask1.180 x 0
Day's range1.1550 - 1.1850
52-week range1.0150 - 2.4700
Volume461,748
Avg. volume917,230
Market cap581.773M
Beta (3Y monthly)2.22
PE ratio (TTM)N/A
EPS (TTM)-0.101
Earnings date26 Feb. 2019 - 4 Mar. 2019
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est2.87
  • GlobeNewswire2 days ago

    Mesoblast Reports Financial Results and Operational Highlights for the First Half Ended December 31, 2018

    MELBOURNE, Australia and NEW YORK, Feb. 20, 2019 -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today reported its financial results and operational highlights for the six months.

  • GlobeNewswire3 days ago

    Final Patient Dosed in Mesoblast Phase 3 Trial of Revascor Cell Therapy for Advanced Heart Failure

    ASX:MSB), a world leader in development and commercialization of cellular medicines, announced today that the last patient has now been dosed in the Phase 3 events-driven trial of its allogeneic cell therapy product candidate Revascor for advanced chronic heart failure. Results from a prior Phase 2 trial identified the patients most likely to benefit from Revascor as being those at high risk of recurrent hospitalization events and death.

  • GlobeNewswire9 days ago

    Mesoblast Financial Results Webcast for Half Year, Q2 Ended December 31, 2018

    NEW YORK and MELBOURNE, Australia, Feb. 13, 2019 -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) will report financial results for the half year and second quarter ended December.

  • GlobeNewswirelast month

    Hercules Capital Provides US$15M From Existing Facility for Mesoblast to Accelerate Product Commercialization Programs

    Nasdaq: MESO) today announced that it has drawn down a further US$15 million from its US$75 million, non-dilutive, four-year credit facility with Hercules Capital, Inc. (HTGC). The funds will be used primarily to ramp up Mesoblast’s product commercialization programs including building out a targeted sales force for its product candidate for acute graft versus host disease (aGVHD). Mesoblast plans to meet with the U.S. FDA during the first half of 2019 to discuss a potential approval pathway for Revascor having met this clinically meaningful outcome in LVAD patients.

  • Why BlueScope Steel, Mesoblast, Wesfarmers, & WiseTech Global shares dropped lower today
    Motley Foollast month

    Why BlueScope Steel, Mesoblast, Wesfarmers, & WiseTech Global shares dropped lower today

    The Wesfarmers Ltd (ASX:WES) share price and the WiseTech Global Ltd (ASX:WTC) share price have dropped lower on Monday. Here's why...

  • Does The Mesoblast Limited (ASX:MSB) Share Price Tend To Follow The Market?
    Simply Wall St.last month

    Does The Mesoblast Limited (ASX:MSB) Share Price Tend To Follow The Market?

    If you're interested in Mesoblast Limited (ASX:MSB), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact Read More...

  • GlobeNewswire2 months ago

    Mesoblast Highlights 2019 Key Priorities for its Leading Cellular Medicines Pipeline at Biotech Showcase in San Francisco

    Nasdaq:MESO), world leader in the development and commercialization of cellular medicines, today reported on commercial and development plans for its lead cellular therapies to Biotech Showcase 2019 being held this week in San Francisco, CA. Mesoblast Chief Executive Dr Silviu Itescu said: "We enter calendar 2019 building upon the successful advancement of our late-stage pipeline where we successfully completed a Phase 3 trial in steroid-refractory acute graft versus host disease (aGVHD) which has near-term commercial potential in the United States (U.S.), and another product candidate having achieved clinical outcomes in line with the U.S. Food and Drug Administration (FDA) guidance for a registrable clinical indication for market authorization, and two additional Phase 3 assets with blockbuster potential.

  • GlobeNewswire2 months ago

    Phase 3 Trial of Mesoblast’s Cell Therapy in Chronic Heart Failure Completes Recruitment

    ASX:MSB), world leader in development and commercialization of allogeneic (off-the-shelf) cellular medicines, today announced that it has completed patient recruitment in the events-driven Phase 3 trial of its product candidate Revascor (MPC-150-IM) for advanced chronic heart failure. Mesoblast Chief Executive Dr Silviu Itescu stated: “Completion of recruitment in this Phase 3 trial, the largest cell therapy trial for heart failure, is a key milestone for Mesoblast and has been achieved on plan.

  • Why the Mesoblast share price stormed 6% higher today
    Motley Fool2 months ago

    Why the Mesoblast share price stormed 6% higher today

    The Mesoblast Limited (ASX:MSB) share price has stormed 6% higher on Monday. Here's why its shares are outperforming the market...

  • GlobeNewswire2 months ago

    Mesoblast Corporate Review

    Mesoblast will enter 2019 with the most mature cell therapy product pipeline and technology platform in the regenerative medicine industry. Two commercial products have already been approved and marketed by the Company’s licensees JCR Pharmaceuticals Co, Ltd. in Japan and Takeda Pharmaceutical Company in Europe. Mesoblast has one product candidate which has successfully completed Phase 3 and with near-term commercial potential in the United States (U.S.), another product candidate having achieved clinical outcomes in line with the U.S. Food and Drug Administration (FDA) guidance for a registrable clinical indication for market authorization, and two additional Phase 3 assets with blockbuster potential. Mesoblast’s royalty income and milestone payments from licensees continues to grow, the Company has sufficient cash to achieve key commercial milestones, and access to additional non-dilutive sources of capital from strategic financial institutions whose extensive due diligence provides further third party validation of the strength of the product portfolio and patent estate.

  • GlobeNewswire2 months ago

    Mesoblast to Present at 2019 Biotech Showcase in San Francisco

    NEW YORK and MELBOURNE, Australia, Dec. 24, 2018 -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO) will report on its Phase 3 trials and commercial plans at the upcoming Biotech.

  • GlobeNewswire2 months ago

    Mesoblast Makes Executive Appointment to Drive Product Commercialization

    ASX:MSB) today announced that it has appointed Eric Strati, PhD, to the new position of Senior Vice President, Commercial. Dr Strati said: “My first priority is to build a highly efficient and targeted field sales team to leverage existing relationships with transplant centers in the United States. Prior to joining Mesoblast in 2015, Dr Strati held various leadership roles in global pharmaceutical companies, most recently at Novartis where he was Executive Director, Managed Markets, and a key member of the successful launch teams for the blockbuster drugs Entresto® in chronic heart failure and Cosentyx® in moderate to severe psoriasis.

  • GlobeNewswire2 months ago

    Meetings Held With FDA Support Mesoblast’s Planned Regulatory Filing for Commercialization of Remestemcel-L in Acute GVHD

    ASX:MSB) today announced that recent meetings held with the United States Food and Drug Administration (FDA) support its planned regulatory filing for commercialization of remestemcel-L in pediatric patients with steroid refractory acute graft versus host disease (aGVHD). Mesoblast gained agreement from the FDA on the proposed chemistry and manufacturing for commercialization. The FDA also provided guidance on the presentation of data from the completed 55-patient Phase 3 trial and the 241-patient Expanded Access Program to be included in the filing for the proposed indication. In the Phase 3 trial, Mesoblast met the pre-specified primary endpoint of improved Day 28 overall response and improved responder survival through Day 180.

  • GlobeNewswire3 months ago

    Tasly and Mesoblast Initiate Development and Regulatory Activities for MPC-150-IM Heart Failure Cell Therapy in China

    NEW YORK and MELBOURNE, Australia, Nov. 26, 2018 -- Tasly Pharmaceutical Group and Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced that the first Joint Steering.

  • 3 Biotech Stocks With Rising Estimates in the Past Month
    Zacks5 months ago

    3 Biotech Stocks With Rising Estimates in the Past Month

    The biotech industry is performing reasonably well. Hence, it is a good idea to select stocks from the sector witnessing positive estimate revisions.